CA2413786A1 - Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes - Google Patents

Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes Download PDF

Info

Publication number
CA2413786A1
CA2413786A1 CA002413786A CA2413786A CA2413786A1 CA 2413786 A1 CA2413786 A1 CA 2413786A1 CA 002413786 A CA002413786 A CA 002413786A CA 2413786 A CA2413786 A CA 2413786A CA 2413786 A1 CA2413786 A1 CA 2413786A1
Authority
CA
Canada
Prior art keywords
rsv
genome
gene
antigenome
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002413786A
Other languages
English (en)
French (fr)
Inventor
Christine D. Krempl
Peter L. Collins
Brian R. Murphy
Ursula Buchholz
Stephen S. Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2413786A1 publication Critical patent/CA2413786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002413786A 2000-06-23 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes Abandoned CA2413786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21370800P 2000-06-23 2000-06-23
US60/213,708 2000-06-23
PCT/US2001/020107 WO2002000693A2 (en) 2000-06-23 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Publications (1)

Publication Number Publication Date
CA2413786A1 true CA2413786A1 (en) 2002-01-03

Family

ID=22796187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002413786A Abandoned CA2413786A1 (en) 2000-06-23 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Country Status (13)

Country Link
EP (1) EP1294858B1 (enExample)
JP (1) JP2004515218A (enExample)
KR (1) KR100899030B1 (enExample)
CN (1) CN1468301A (enExample)
AT (1) ATE416251T1 (enExample)
AU (3) AU2001268709B2 (enExample)
BR (1) BRPI0112276B8 (enExample)
CA (1) CA2413786A1 (enExample)
DE (1) DE60136811D1 (enExample)
ES (1) ES2317914T3 (enExample)
IL (1) IL153530A0 (enExample)
MX (1) MXPA02012818A (enExample)
WO (1) WO2002000693A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101260386A (zh) 1999-07-09 2008-09-10 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN105200069A (zh) * 2015-10-16 2015-12-30 北京交通大学 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用
KR20180085802A (ko) 2015-12-11 2018-07-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ns1 및 ns2 유전자 이동을 포함하는 재조합 rsv 균주
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
US20230279362A1 (en) * 2020-06-05 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Live attenuated respiratory syncytial virus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Also Published As

Publication number Publication date
ES2317914T3 (es) 2009-05-01
AU2001268709B2 (en) 2006-09-28
BR0112276A (pt) 2004-02-10
IL153530A0 (en) 2003-07-06
BRPI0112276B1 (pt) 2019-12-31
KR100899030B1 (ko) 2009-05-21
CN1468301A (zh) 2004-01-14
BRPI0112276B8 (pt) 2021-05-25
ATE416251T1 (de) 2008-12-15
WO2002000693A3 (en) 2002-09-26
EP1294858A2 (en) 2003-03-26
JP2004515218A (ja) 2004-05-27
EP1294858B1 (en) 2008-12-03
KR20030045685A (ko) 2003-06-11
MXPA02012818A (es) 2003-05-14
AU2006252238A1 (en) 2007-01-25
AU6870901A (en) 2002-01-08
DE60136811D1 (de) 2009-01-15
WO2002000693A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
US7829102B2 (en) Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
EP0912724B1 (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) Attenuated chimeric respiratory syncytial virus
US6923971B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
EP1690940A1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7744902B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
AU2001268709B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
US7662397B2 (en) Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
AU2001268709A1 (en) Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
US7820182B2 (en) Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
US7485440B2 (en) Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
AU2005201040A1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130219